Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | APAF1 | O14727 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382248 | 0.85 | MAPT (0.43) | RAB9AALDH1A1MAPTAPAF1PKM | |
| SCHEMBL3867031 | 0.85 | KDM4E (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL3867984 | 0.84 | HSD17B10 (0.46) | PADI4RAB9AALDH1A1MAPTAPAF1 | |
| SCHEMBL2383970 | 0.83 | KDM4E (0.37) | PADI4RAB9AALDH1A1MAPTAPAF1 | |
| SCHEMBL3445477 | 0.83 | KDM4E (0.40) | PADI4RAB9AALDH1A1MAPTAPAF1 | |
| SCHEMBL2385054 | 0.83 | MAPT (0.46) | RAB9AALDH1A1MAPTAPAF1PKM | |
| SCHEMBL3443882 | 0.82 | KDM4E (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL2385861 | 0.81 | KDM4E (0.41) | RAB9AALDH1A1MAPTAPAF1PKM | |
| SCHEMBL2384375 | 0.81 | KDM4E (0.41) | RAB9AALDH1A1MAPTAPAF1PKM | |
| Hydrochloric Acid SCHEMBL3444526 | 0.81 | KDM4E (0.42) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012991-B2 | 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate | SANOFI-AVENTIS (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | US | disclosed |
| US-7390818-B2 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-06-24 | — | — | US | disclosed |
| EP-1556382-B1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-28 | — | — | EP | disclosed |
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-12-29 | — | — | US | disclosed |
| EP-1556382-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041817-A1 | 3-PHENYL SUBSTITUTED PYRIDOINDOLONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288318-A1 | Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics | PNPO, PDXK, PLPBP | PADI4 2444/4885GABRA1 1812/4885GABRG2 2796/4885 |
| US-20080214538-A1 | Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics | PNPO, PLPBP, DPYD | PADI4 3708/4885GABRA1 2339/4885GABRG2 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.